ATE466869T1 - Verfahren zur herstellung von immunogenen hla- a2.1-bindenden peptiden - Google Patents

Verfahren zur herstellung von immunogenen hla- a2.1-bindenden peptiden

Info

Publication number
ATE466869T1
ATE466869T1 AT94910837T AT94910837T ATE466869T1 AT E466869 T1 ATE466869 T1 AT E466869T1 AT 94910837 T AT94910837 T AT 94910837T AT 94910837 T AT94910837 T AT 94910837T AT E466869 T1 ATE466869 T1 AT E466869T1
Authority
AT
Austria
Prior art keywords
binding peptides
producing immunogenic
hla
peptides
immunogenic hla
Prior art date
Application number
AT94910837T
Other languages
English (en)
Inventor
Howard M Grey
Alessandro Sette
John Sidney
W Martin Kast
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Application granted granted Critical
Publication of ATE466869T1 publication Critical patent/ATE466869T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
AT94910837T 1993-03-05 1994-03-04 Verfahren zur herstellung von immunogenen hla- a2.1-bindenden peptiden ATE466869T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2714693A 1993-03-05 1993-03-05
US7320593A 1993-06-04 1993-06-04
US15918493A 1993-11-29 1993-11-29
PCT/US1994/002353 WO1994020127A1 (en) 1993-03-05 1994-03-04 Hla-a2.1 binding peptides and their uses

Publications (1)

Publication Number Publication Date
ATE466869T1 true ATE466869T1 (de) 2010-05-15

Family

ID=27362951

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94910837T ATE466869T1 (de) 1993-03-05 1994-03-04 Verfahren zur herstellung von immunogenen hla- a2.1-bindenden peptiden

Country Status (12)

Country Link
EP (1) EP0703783B1 (de)
JP (1) JP3908271B2 (de)
KR (1) KR960700739A (de)
CN (1) CN1118572A (de)
AT (1) ATE466869T1 (de)
AU (2) AU6359494A (de)
BR (1) BR9406652A (de)
CA (1) CA2157510A1 (de)
DE (1) DE69435292D1 (de)
NZ (1) NZ263050A (de)
SG (1) SG49008A1 (de)
WO (1) WO1994020127A1 (de)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US6689363B1 (en) 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US20020168374A1 (en) * 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
US5651993A (en) 1992-11-18 1997-07-29 Yale University Specific immune system modulation
US6328971B1 (en) * 1993-01-22 2001-12-11 Ludwig Institute For Cancer Research MAGE-1 derived nona peptides, and compositions thereof
EP1375511B1 (de) * 1993-02-26 2007-04-11 The Scripps Research Institute Peptide zum Induzieren einer Antwort der zytotoxischen T-Lymphozyten gerichtet gegen das Hepatitis-B-Virus
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
NZ271531A (en) * 1993-08-02 1998-02-26 Scripps Research Inst Peptide which induces cytotoxic t lymphocyte responses to heptatitis b antigens
NZ271774A (en) * 1993-08-06 1998-02-26 Cytel Corp Immunogenic peptides from the c-terminus of the mage-1 (melanoma) antigen
DK0735893T3 (da) 1993-09-14 2009-03-09 Pharmexa Inc PAN DR-bindende peptider til styrkelse af immunsvaret
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
US5756666A (en) * 1993-10-19 1998-05-26 Ajinomoto Co., Inc. Peptides capable of inducing immune response to HIV
US5550214A (en) * 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
US5554506A (en) * 1994-03-24 1996-09-10 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5851523A (en) * 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5585461A (en) * 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
WO1995027733A1 (en) * 1994-04-08 1995-10-19 The Government Of The United States Of America, Represented By The Department Of Health & Human Services Hepatitis c virus core peptide for stimulation of cytotoxic t lymphocytes and diagnosis of hcv exposure
US5935797A (en) * 1994-06-16 1999-08-10 Stanford University Interaction of MHC Class II proteins with members of the PCNA family of proteins
SE9403526D0 (sv) 1994-10-14 1994-10-14 Astra Ab New Peptides
AU712441B2 (en) 1994-12-14 1999-11-04 Scripps Research Institute, The In vivo activation of tumor-specific cytotoxic T cells
US6057294A (en) * 1995-01-16 2000-05-02 Northern Sydney Area Health Service Of Pacific Highway Peptide
GB9501300D0 (en) * 1995-01-24 1995-03-15 Boughton Brian J Peptides which inhibit viruses
US5874531A (en) * 1995-03-07 1999-02-23 President And Fellows Of Harvard College Identification of self and non-self antigens implicated autoimmune disease
US6514942B1 (en) * 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
SE9501067D0 (sv) 1995-03-24 1995-03-24 Astra Ab New peptides
US6156316A (en) * 1995-05-08 2000-12-05 Sloan-Kettering Institute For Cancer Research Oncogene fusion protein peptide vaccines
US5698396A (en) * 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
US6140464A (en) * 1995-06-07 2000-10-31 Ludwig Institute For Cancer Research Nonapeptides that bind a HLA-A2.1 molecule
US5858972A (en) * 1996-01-11 1999-01-12 La Jolla Cancer Research Foundation Antithrombotic agents and methods of use
DE69714011T2 (de) * 1996-01-24 2003-02-27 Epimmune Inc Die erzeugung einer immunantwort gegen erwünschte determinanten
US5723579A (en) * 1996-02-02 1998-03-03 Bayer Corporation Fibrinogen binding peptides
US6143509A (en) * 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
US7001600B1 (en) 1996-02-09 2006-02-21 The United States Of America As Represented By The Secretary Of Health And Human Services Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
US6946133B1 (en) 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide
EP1767542B1 (de) * 1996-03-21 2016-05-11 Epimmune Inc. HLA-A2.1 bindende Peptide und deren Verwendung
CA2248667C (en) * 1996-03-21 2012-06-05 Epimmune Inc. Hla-a2.1 binding peptides and their uses
DE69739001D1 (de) 1996-06-11 2008-10-30 Northern Sydney And Central Co T zell antigen rezeptor peptide
US6465251B1 (en) 1996-11-13 2002-10-15 Dana-Farber Cancer Institute, Inc. Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin
US6287756B1 (en) * 1997-05-05 2001-09-11 Ludwig Institute For Cancer Research Methods for determining presence of cancer in a sample by determining expression of an SSX gene
WO1999006599A1 (en) * 1997-08-01 1999-02-11 Genetic Systems Corporation Synthetic antigen for the detection of antibodies immunoreactive with hiv virus
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
EP1049711B1 (de) * 1998-01-19 2003-12-10 Mogam Biotechnology Research Institute Liposomen, enthaltend peptidantigene, welche vom x-protein aus hepatitis b virus abstammen
WO1999040930A1 (en) 1998-02-12 1999-08-19 Center For Blood Research, Inc. Specific inhibitors of nfat activation by calcineurin and their use in treating immune-related diseases
US20040002117A1 (en) 1998-02-12 2004-01-01 Hogan Patrick G. Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases
US6734287B1 (en) 1998-04-09 2004-05-11 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
EP0955311A3 (de) * 1998-04-09 2000-08-16 Idexx Laboratories, Inc. Peptidscher Impfstoff für Hundenallergie
DE69940774D1 (de) * 1998-06-17 2009-06-04 Idm Pharma Inc Hla-bindende peptide und ihre verwendungen
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
EP1108023B1 (de) * 1998-09-01 2007-08-15 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Page-4, ein gage-ähnliches gen auf dem x-chromosom das von neoplastischer prostata, testis und uterus exprimiert wird, und dessen anwendungen
GB9826143D0 (en) * 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
IT1309584B1 (it) * 1999-02-26 2002-01-24 San Raffaele Centro Fond Peptidi immunogenici derivati da mage-3 presentati da mhc di classeii e loro uso.
AU757334B2 (en) * 1999-03-30 2003-02-13 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
JP2002540217A (ja) * 1999-03-30 2002-11-26 アイデックス ラボラトリーズ インコーポレイテッド イヌアレルギー用ペプチドワクチン
AU782391B2 (en) 1999-04-20 2005-07-21 Richard Leslie Edelson Differentiation of monocytes into functional dendritic cells
ATE512666T1 (de) * 1999-06-29 2011-07-15 Epimmune Inc Hla-bindende peptide und ihre verwendungen
US7129052B1 (en) 2000-07-12 2006-10-31 The United States Of America As Represented By The Department Of Health And Human Services Peptides and their utility in modulation of behavior of cells expressing α3β1 integrins
AU1075001A (en) * 1999-10-05 2001-05-10 Epimmune, Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
CA2386341A1 (en) 1999-11-18 2001-05-25 Epimmune Inc. Heteroclitic analogs and related methods
WO2001042281A1 (en) * 1999-12-06 2001-06-14 Hôpital Sainte-Justine Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US6602510B1 (en) 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
CA2393730A1 (en) * 1999-12-13 2001-06-14 Epimmune Inc. Hla class i a2 tumor associated antigen peptides and vaccine compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
MXPA02008219A (es) * 2000-02-23 2005-06-30 Epimmune Inc Peptidos que enlazan hla y sus usos.
US7268207B2 (en) 2000-04-04 2007-09-11 University Of Rochester Gene differentially expressed in breast and bladder cancer, and encoded polypeptides
EP2363139B1 (de) * 2000-05-12 2016-03-02 NorthWest Biotherapeutics, Inc. Verfahren zur Steigerung der Klasse I Darstellung von exogenen Antigenen durch humane dendritische Zellen
FR2809402A1 (fr) * 2000-05-26 2001-11-30 Dev Des Antigenes Combinatoire Bibliotheques peptidiques combinatoires convergentes et leur application a la vaccination contre le virus de l'hepatite c
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
ATE403716T1 (de) 2000-08-28 2008-08-15 Agensys Inc Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen
AU2000275748A1 (en) * 2000-09-01 2002-03-22 Epimmune, Inc. Hla-a2.1 binding peptides and their uses
EP1195381A1 (de) * 2000-09-28 2002-04-10 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
ATE536187T1 (de) 2000-10-19 2011-12-15 Epimmune Inc Hla-klasse-i- und -klasse-ii-bindende peptide und ihre verwendungen
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
CA2441947C (en) * 2001-03-23 2014-05-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Human papilloma virus immunoreactive peptides
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
JP2005500058A (ja) 2001-08-17 2005-01-06 ネオーズ テクノロジーズ， インコーポレイテッド シアリル化したオリゴサッカリドの化学的酵素的合成
JP2005505271A (ja) 2001-09-06 2005-02-24 アジェンシス， インコーポレイテッド 癌の処置および検出において有用なｓｔｅａｐ−１と名称が与えられる核酸および対応するタンパク質
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
FR2839722A1 (fr) 2002-05-17 2003-11-21 Bio Merieux Nouvelles compositions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
AU2003274463B2 (en) 2002-06-10 2009-10-29 University Of Rochester Gene differentially expressed in breast and bladder cancer and encoded polypeptides
EP1523557A2 (de) 2002-07-24 2005-04-20 Intercell AG Bei alternativen leserahmen kodiertete antigenen aus pathogenischen viren
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
EP1545610A4 (de) * 2002-09-06 2006-11-08 Mannkind Corp Epitop-sequenzen
EP1537418A2 (de) 2002-09-13 2005-06-08 Intercell AG Verfahren zur isolierung von hepatitis c virus peptiden
AU2003291632A1 (en) 2002-10-03 2004-04-23 Epimmune Inc Hla binding peptides and their uses
EP1903056A3 (de) 2002-12-10 2008-05-07 Idm Pharma, Inc. HLA-A1, -A2, -A3, -A24, -B7 and -B44 bindende Peptide die Tumorassoziiert-Antigen Epitopen enthalten, und Zusammensetzungen davon
WO2004058807A2 (en) * 2002-12-24 2004-07-15 Algonomics N.V. Mhc class i restricted t-cell stimulating peptides from hepatitis b virus
EP2343315A3 (de) 2003-02-10 2011-11-23 Agensys, Inc. Nukleinsäure und entsprechendes Protein mit der Bezeichnung 158P1D7, das sich für die Behandlung und den Nachweis von Blasenkrebs und anderen Krebserkrankungen eignet
EP1605963B1 (de) 2003-02-14 2011-11-16 Provid Pharmaceuticals, Inc. Hemmer der antigenpräsentation über mhc-klasse-ii-moleküle und verwendungsverfahren dafür
ATE485056T1 (de) 2003-03-24 2010-11-15 Intercell Ag Verbesserte impfstoffe
WO2004092207A2 (en) * 2003-04-16 2004-10-28 Algonomics N.V. Respiratory syncytial virus (rsv) peptides
WO2004094454A2 (en) 2003-04-18 2004-11-04 Idm Pharma, Inc. Hla-a2 tumor associated antigen peptides and compositions
US7622564B2 (en) 2003-05-30 2009-11-24 Agensys, Inc. Prostate stem cell antigen (PSCA) variants and subsequences thereof
ATE489967T1 (de) 2003-07-11 2010-12-15 Intercell Ag Hcv-vakzin
WO2005007694A1 (ja) * 2003-07-16 2005-01-27 Green Peptide Co., Ltd. ＨＥＲ２／ｎｅｕペプチドおよびその治療上の用途
EP1676856A4 (de) * 2003-09-22 2008-03-05 Greenpeptide Co Ltd Aus dem hepatitis c virus stammendes peptid
US7348007B2 (en) * 2004-02-09 2008-03-25 Ludwig Institute For Cancer Research Mage C2 antigenic peptides and uses thereof
JP4761311B2 (ja) * 2004-04-30 2011-08-31 日本電気株式会社 Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター
PL1753871T3 (pl) 2004-05-28 2016-01-29 Agensys Inc Przeciwciała i powiązane cząsteczki, które wiążą się z antygenem komórek macierzystych prostaty (PSCA)
US7785875B2 (en) 2004-07-03 2010-08-31 Mogam Biotechnology Research Institute Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
KR100790646B1 (ko) * 2004-07-03 2008-01-02 재단법인 목암생명공학연구소 세포매개 면역반응을 효과적으로 유도하는 ｈｃｖ수퍼타입 에피토프, 그를 코딩하는 올리고뉴클레오타이드및 그의 용도
ITRM20050297A1 (it) * 2005-06-08 2006-12-09 Univ Siena Anticorpi diretti contro la proteina basica della mielina che riconoscono un epitopo del cd64 e uso di essi come immunodepressivi.
FR2887884B1 (fr) * 2005-06-29 2007-09-14 Pasteur Institut Epitopes de la proteine hbsp et leurs applications biotechnologiques et medicales, notamment pour le traitement de l'hepatite b chronique
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
CA2812794C (en) * 2005-09-08 2020-02-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine, C. Targeted identification of immunogenic peptides
WO2007091387A1 (ja) * 2006-02-07 2007-08-16 Nec Corporation Ｈｌａ結合性ペプチド、その前駆体、それをコードするｄｎａ断片および組み換えベクター
JPWO2008044567A1 (ja) 2006-10-12 2010-02-12 日本電気株式会社 Ｈｌａ結合性ペプチド、その前駆体、それをコードするｄｎａ断片および組み換えベクター
WO2009059011A2 (en) 2007-11-01 2009-05-07 Mayo Foundation For Medical Education And Research Hla-dr binding peptides and their uses
DE102007059924A1 (de) * 2007-12-03 2009-06-04 Eberhard-Karls-Universität Tübingen Universitätsklinikum Allel- und Isotyp-spezifische Intervention an mit Autoimmunerkrankungen assoziierten MHC-Klasse-II-Molekülen durch Peptide
EP2234632B1 (de) * 2008-01-10 2014-10-29 Endocrine Pharmaceuticals Limited Proteinöse verbindungen
US9249187B2 (en) * 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
US8986712B2 (en) * 2009-11-29 2015-03-24 Yeda Research And Development Co., Ltd. Peptides derived from HIV-1 gp41 transmembrane domain for t-immunomodulation
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
CN110291402B (zh) 2016-06-27 2023-09-01 朱诺治疗学股份有限公司 鉴定肽表位的方法、结合此类表位的分子和相关用途
CA3058807A1 (en) 2017-04-03 2018-10-11 Neon Therapeutics, Inc. Protein antigens and uses thereof
KR20230008254A (ko) 2017-11-08 2023-01-13 바이오엔테크 유에스 인크. T 세포 제조 조성물 및 방법
FR3087448B1 (fr) 2018-10-23 2023-10-13 Pdc Line Pharma Lignee pdc modifiee pour secreter une cytokine
WO2020086927A1 (en) * 2018-10-26 2020-04-30 Saint Louis University Peptides for inducing heterosubtypic influenza t cell responses
JP2023539055A (ja) 2020-08-13 2023-09-13 ビオンテック ユーエス インコーポレイテッド Ｒａｓネオ抗原およびその使用
WO2022036137A1 (en) 2020-08-13 2022-02-17 Biontech Us Inc. T cell manufacturing compositions and methods
CA3202176A1 (en) 2020-12-14 2022-06-23 Michael Steven ROONEY Tissue-specific antigens for cancer immunotherapy
WO2023049272A1 (en) 2021-09-22 2023-03-30 Biontech Us Inc. Coronavirus vaccines and methods of use
WO2023064612A2 (en) 2021-10-15 2023-04-20 BioNTech SE Pharmaceutical compositions for delivery of viral antigens and related methods
WO2023147090A1 (en) 2022-01-27 2023-08-03 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US5679641A (en) * 1992-05-26 1997-10-21 Rijksuniversiteit Leiden Peptides of human P53 protein for use in human T cell response inducing compositions, and human P53 protein-specific cytotoxic t-lymphocytes
AU4998993A (en) * 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses
DE4238416A1 (de) * 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
IL109664A0 (en) * 1993-05-18 1994-08-26 Rijksuniversiteit Peptides of human influenza virus for use in human t cell response inducing compositions
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor

Also Published As

Publication number Publication date
CA2157510A1 (en) 1994-09-15
DE69435292D1 (de) 2010-06-17
KR960700739A (ko) 1996-02-24
BR9406652A (pt) 1996-09-10
WO1994020127A1 (en) 1994-09-15
NZ263050A (en) 1997-11-24
CN1118572A (zh) 1996-03-13
JPH08507525A (ja) 1996-08-13
JP3908271B2 (ja) 2007-04-25
SG49008A1 (en) 1998-05-18
WO1994020127A9 (en) 2003-04-17
AU6597998A (en) 1998-07-02
AU6359494A (en) 1994-09-26
EP0703783A4 (de) 1999-03-10
EP0703783B1 (de) 2010-05-05
EP0703783A1 (de) 1996-04-03

Similar Documents

Publication Publication Date Title
ATE466869T1 (de) Verfahren zur herstellung von immunogenen hla- a2.1-bindenden peptiden
EP0907370A4 (de) Hla-a2.1 bindende peptide und deren verwendung
IL106610A0 (en) Hla binding peptides and their uses
EP1189624A4 (de) Hla-bindende peptide und deren verwendung
EP1911461A3 (de) HLA-Klasse-I- und -Klasse-II-bindende Peptide und ihre Verwendungen
ATE224184T1 (de) Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
HK1013832A1 (en) Methods of producing analgesia and enhancing opiate analgesia
DE69635895D1 (de) Antigen presentierende bläschen, die von zellen ableiten
ATE391783T1 (de) Verfahren und reagenzien zur erzeugung einer cd8+ t-zellen immunantwort gegen melanoma
GB9624456D0 (en) Assay method
ATE319745T1 (de) Verfahren zur herstellung von nicht-immunogenen proteinen
FI963779A0 (fi) MAGE-kasvainhyljintäantigeeniprekursoreista saatuja eristettyjä peptidejä, jotka kompleksoituvat HLA-A2-molekyylien kanssa
ATE149523T1 (de) Verfahren zur herstellung von interferon-alpha-2 kristallen
DE3688632D1 (de) Verfahren zur herstellung von peptiden in fester phase.
EP1089757A4 (de) Hla-bindende peptide und ihre verwendungen.
MY102593A (en) Antigents of plasmodium falciparum
ES2006730A6 (es) Un metodo de preparar un peptido o polipeptido sintetico que presenta la antigenicidad de la totalidad o una parte de un antigeno de p. falciparum
EP0317279A3 (de) Peptide für die Verwendung zur Reinigung von Faktor-VIII
DE3485883T2 (de) Rekombinante materialien und verfahren zur herstellung von menschliche konnektive gewebe aktivierende peptide iii und deren analoge.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties